UK & ROI
Consumer
Search
Product search
Practitioner home > Our Products > Biofinity family > Biofinity® & Biofinity® XR

Biofinity® & Biofinity® XR

  • World-class design, incredible comfort, clear vision and a healthy lens-wearing experience that your patients will love.*1,2
Product specs

Description

Biofinity® and Biofinity® XR are monthly replacement silicone hydrogel lenses for myopic and hyperopic patients, including those with higher prescriptions.

Features and Benefits

  • Aquaform® Technology for incredible all-day comfort that lasts1
  • Aberration Neutralising System™ for clear and crisp vision1
  • Highly breathable to help keep eyes clear, white and healthy1
  • Naturally wettable with no need for surface treatments or coatings1
  • Available for 99.995% of prescriptions, with sphere powers from +15.00D to -20.00D, so you can meet the needs of more patients3,4
  • Predictable, consistent fitting for high rates of first-fit success†5,6
  • Suitable for overnight wear of up to 6 nights and 7 days.7

 

Aquaform® Technology

Aquaform® Technology allows water to be held throughout each Biofinity® lens material, from its core to its surface, helping to keep it moist all day long.2 This provides natural wettability, without coatings or surface treatments to support an incredibly comfortable lens-wearing experience.2

 

Aberration Neutralising System™

Aspheric front surface design unique by lens power. It is designed to help counteract the eye's average spherical aberration, leading to clear vision.†1

Product Details

Material / H20 content
comfilcon A / 48%
Replacement schedule
Monthly Replacement
Oxygen transmissibility
171 Dk/t (at -3.00D)
Thickness
Biofinity® 0.08mm (@ -3.00DS) / Biofinity® XR Varies by Rx
Revenue carton size
3 and 6
Base curve
Biofinity®
8.6mm
Biofinity® XR
8.6mm
Diameter
14.0mm
14.0mm
Sphere power
-12.00 to -6.50DS (0.50D steps)
-6.00 to -0.25DS (0.25D steps)
+0.25 to +6.00DS (0.25D steps)
+6.50 to +8.00DS (0.50D steps)
-20.00 to -12.50DS (0.50D steps)
+8.50 to +15.00DS (0.50D steps)

Packaging images for illustration purposes only.


* On average, 84% strongly/somewhat agree.
† On average, 87% strongly/somewhat agree.

References:
1. CVI data on file, 2024.
2. CVI data on file 2021. Decision Analyst online survey of 1,027 Biofinity® wearers aged 16-65 years in USA, Japan, Germany, France and Spain.
3. CVI data on file, 2020. Rx coverage database; 14 to 70 years; Rx with <0.75DC.
4. CVI data on file, 2020. Rx coverage database n=101,973 aged 14 to 70 years.
5. CVI data on file, 2019. Randomised, double-masked, crossover study, habitual CL wearers fitted with Biofinity® for 1/12 then MyDay for 1/52. N=55.
6. CVI data on file 2021. Decision Analyst online survey of 376 Biofinity® prescribing ECPs in USA, Japan, Germany, France and Spain.
7. A.M. Moezzi, et al. Overnight Corneal Swelling, CLAO; 32(6): 277–280.

For the device safety, warnings, precaution, and local regulatory information, please refer to the Instruction for Use leaflet.

 

SA13065 / APP135593